Neoadjuvant radiotherapy and radiochemotherapy: Standards and perspectives;Neoadjuvante radiotherapie und radiochemotherapie: Standards und ausblick

Viszeralchirurgie

Volumn 41, Issue 5, 2006, Pages 333-337

  Rödel, Claus ^a   Sauer, R ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Combined modality treatment; Neoadjuvant; Rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; OXALIPLATIN;

ADJUVANT THERAPY; ARTICLE; CANCER REGRESSION; CHEMOTHERAPY; DIARRHEA; FATIGUE; HUMAN; LEUKOPENIA; NEUROTOXICITY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PROCTITIS; RADIATION; RECTUM CANCER; SURGICAL TECHNIQUE; TREATMENT PLANNING;

EID: 33751019494     PISSN: 14353067     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-942197     Document Type: Article

References (26)

1. Merkel S, Mansmann U, Siassi M et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16: 298-304
2. Schmiegel W, Pox C, Adler G et al. [S3-guideline conference "Colorectal Cancer" 2004]. Dtsch Med Wochenschr 2005 (Suppl 1); 130: S5-S53
3. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8 507 patients from 22 randomised trials. Lancet 2001; 358: 1291-1304
4. Camma C, Giunta M, Fiorica F et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. Jama 2000; 284: 1008-1015
5. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646
6. Marijnen CA, Peeters K, Putter H et al. Long term results, toxicity and quality of life in the TME trial. Proc Am Soc Clin Oncol 2005; abstract number 166
7. Rödel C, Grabenbauer GG, Schick C et al. Preoperative radiation with concurrent 5-fluorouracil for locally advanced T4-primary rectal cancer. Strahlenther Onkol 2000; 176: 161-167
8. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740
9. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24
10. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992; 10: 549-557
11. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-715
12. Tveit KM, Guldvog I, Hagen S et al. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br J Surg 1997; 84: 1130-1135
13. Bosset JF, Calais G, Mineur L et al. Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial. J Clin Oncol 2005; 23: 247
14. Gerard JP, Bonnetain F, Conroy T et al. Preoperative (preop) radiotherapy (RT)+ 5 FU/folinic acid (FA) in T3-4 rectal cancers: results of the FFCD 9203 randomized trial. J Clin Oncol 2005; 23: 247
15. Gunderson LL, Sargent DJ, Tepper JE et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys 2002; 54: 386-396
16. Rodel C, Grabenbauer GG, Papadopoulos T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104
17. Gerard JP, Chapet O, Nemoz C et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 2003; 21: 1119-1124
18. Carraro S, Roca EL, Cartelli C et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTG1 study. Int J Radiat Oncol Biol Phys 2002; 54: 397-402
19. Aschele C, Friso ML, Pucciarelli S et al. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 2005; 16: 1140-1146
20. Machiels JP, Duck L, Honhon B et al. Phase II study of preoperative oxaliplatin, capedtabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 2005; 16: 1898-1905
21. Sebag-Montefiore D, Glynne-Jones R, Falk S et al. A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer 2005; 93: 993-998
22. Ryan DP, Niedzwiecki D, Hollis D et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006; 24: 2557-2562
23. Mehta VK, Cho C, Ford JM et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003; 55: 132-137
24. Klautke G, Feyerherd P, Ludwig K et al. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer 2005; 92: 1215-1220
25. Mohiuddin M, Winter K, Mitchell E et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24: 650-655
26. Klautke G, Kuchenmeister U, Foitzik T et al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 2006; 94: 976-981